• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸膜和腹膜间皮瘤的预期寿命

Life Expectancy in Pleural and Peritoneal Mesothelioma.

作者信息

Shavelle Robert, Vavra-Musser Kate, Lee Jessica, Brooks Jordan

机构信息

Life Expectancy Project, San Francisco, CA, USA.

出版信息

Lung Cancer Int. 2017;2017:2782590. doi: 10.1155/2017/2782590. Epub 2017 Jan 23.

DOI:10.1155/2017/2782590
PMID:28239496
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5292397/
Abstract

. Mesothelioma is a rare cancer with a historically dire prognosis. We sought to calculate life expectancies for patients with pleural or peritoneal mesothelioma, both at time of diagnosis and several years later, and to examine whether survival has improved in recent years. . Data on 10,258 pleural and 1,229 peritoneal patients from the SEER US national cancer database, 1973-2011, were analyzed using the Cox proportional hazards regression model. . The major factors related to survival were age, sex, stage, grade, histology, and treatment. Survival improved only modestly over the study period: 0.5% per year for pleural and 2% for peritoneal. . Life expectancies were markedly reduced from normal, even amongst 5-year survivors with the most favorable characteristics and treatment options.

摘要

间皮瘤是一种罕见的癌症,其预后历来很差。我们试图计算胸膜或腹膜间皮瘤患者在诊断时以及数年后的预期寿命,并研究近年来生存率是否有所提高。对1973年至2011年美国监测、流行病学和最终结果(SEER)国家癌症数据库中10258例胸膜间皮瘤患者和1229例腹膜间皮瘤患者的数据,使用Cox比例风险回归模型进行分析。与生存相关的主要因素包括年龄、性别、分期、分级、组织学和治疗。在研究期间,生存率仅略有提高:胸膜间皮瘤患者每年提高0.5%,腹膜间皮瘤患者每年提高2%。即使是具有最有利特征和治疗选择的5年幸存者,其预期寿命也明显低于正常水平。

相似文献

1
Life Expectancy in Pleural and Peritoneal Mesothelioma.胸膜和腹膜间皮瘤的预期寿命
Lung Cancer Int. 2017;2017:2782590. doi: 10.1155/2017/2782590. Epub 2017 Jan 23.
2
Life expectancy in pancreatic neuroendocrine cancer.胰腺神经内分泌肿瘤的预期寿命。
Clin Res Hepatol Gastroenterol. 2019 Feb;43(1):88-97. doi: 10.1016/j.clinre.2018.08.005. Epub 2018 Sep 13.
3
Life Expectancy After Liver Transplantation for Hepatocellular Carcinoma With Cirrhosis.肝硬化肝细胞癌肝移植后的预期寿命。
Prog Transplant. 2021 Mar;31(1):62-71. doi: 10.1177/1526924820978603.
4
Malignant pleural mesothelioma: a population-based study of survival.恶性胸膜间皮瘤:一项基于人群的生存研究。
J Thorac Oncol. 2010 Nov;5(11):1841-8. doi: 10.1097/JTO.0b013e3181f1cf2b.
5
Survival of peritoneal malignant mesothelioma in Italy: a population-based study.意大利腹膜恶性间皮瘤的生存率:一项基于人群的研究。
Int J Cancer. 2009 Jan 1;124(1):194-200. doi: 10.1002/ijc.23866.
6
Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005.监测、流行病学与最终结果(SEER)数据库中的胸膜和腹膜间皮瘤:年龄效应及时间趋势,1973 - 2005年
Cancer Causes Control. 2009 Aug;20(6):935-44. doi: 10.1007/s10552-009-9328-9. Epub 2009 Mar 18.
7
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.接受胸膜外全肺切除术的恶性胸膜间皮瘤患者 3 年生存的临床和病理特征。
Eur J Cardiothorac Surg. 2011 Aug;40(2):298-303. doi: 10.1016/j.ejcts.2010.12.024. Epub 2011 Feb 9.
8
[Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].[下诺曼底地区的恶性间皮瘤,一项法国人群研究。描述性分析、预后因素及生存情况]
Rev Epidemiol Sante Publique. 2001 Dec;49(6):523-9.
9
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.症状与患者报告的健康状况:它们能否预测恶性胸膜间皮瘤的生存率?欧洲癌症研究与治疗组织-加拿大国立癌症研究所08983研究的预后因素分析:顺铂联合或不联合雷替曲塞治疗恶性胸膜间皮瘤患者的随机III期研究
J Clin Oncol. 2007 Dec 20;25(36):5770-6. doi: 10.1200/JCO.2007.12.5294.
10
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.细胞减灭术联合奥沙利铂腹腔热灌注化疗治疗腹膜间皮瘤:初步结果及生存分析
Surg Oncol. 2015 Mar;24(1):41-6. doi: 10.1016/j.suronc.2014.12.002. Epub 2015 Jan 8.

引用本文的文献

1
Identification of a novel prognostic gene signature in pleural mesothelioma: a study based on The Cancer Genome Atlas database and experimental validation.胸膜间皮瘤中一种新型预后基因特征的鉴定:基于癌症基因组图谱数据库的研究及实验验证
Transl Cancer Res. 2025 May 30;14(5):2981-2998. doi: 10.21037/tcr-2024-2531. Epub 2025 May 27.
2
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.KEYNOTE-A17:帕博利珠单抗联合顺铂-培美曲塞一线治疗日本晚期胸膜间皮瘤患者
Cancer Sci. 2025 Aug;116(8):2208-2217. doi: 10.1111/cas.70082. Epub 2025 May 23.
3
Computer-Aided Discovery of Natural Compounds Targeting the ADAR2 dsRBD2-RNA Interface and Computational Modeling of Full-Length ADAR2 Protein Structure.靶向ADAR2双链RNA结合结构域2-RNA界面的天然化合物的计算机辅助发现及全长ADAR2蛋白质结构的计算建模
Int J Mol Sci. 2025 Apr 25;26(9):4075. doi: 10.3390/ijms26094075.
4
Bidirectional Mendelian randomization and potential mechanistic insights into the causal relationship between gut microbiota and malignant mesothelioma.双向孟德尔随机化研究及对肠道微生物群与恶性间皮瘤因果关系的潜在机制见解
Medicine (Baltimore). 2025 Apr 25;104(17):e42245. doi: 10.1097/MD.0000000000042245.
5
The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.间皮瘤全身炎症评分与总生存期独立相关,并可预测胸膜间皮瘤多模式治疗的获益情况。
Cancers (Basel). 2025 Apr 20;17(8):1371. doi: 10.3390/cancers17081371.
6
Mesothelioma Incidence Rates in Australia since 1982: Exploring Age, Period, and Cohort Effects and Future Projections.1982年以来澳大利亚间皮瘤发病率:探讨年龄、时期和队列效应及未来预测
Cancer Epidemiol Biomarkers Prev. 2025 Jul 1;34(7):1149-1155. doi: 10.1158/1055-9965.EPI-24-1224.
7
Development and validation of a prognostic nomogram for patients with malignant peritoneal mesothelioma.恶性腹膜间皮瘤患者预后列线图的开发与验证
Front Oncol. 2025 Feb 28;15:1480197. doi: 10.3389/fonc.2025.1480197. eCollection 2025.
8
Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review.帕博利珠单抗作为弥漫性恶性腹膜间皮瘤的有效治疗方法并实现长期生存:一例病例报告及文献综述
Oncol Lett. 2025 Feb 13;29(4):187. doi: 10.3892/ol.2025.14933. eCollection 2025 Apr.
9
Establishment and bioinformatics analysis of a four-miRNA prognostic signature for pleural mesothelioma.用于胸膜间皮瘤的四miRNA预后特征的建立及生物信息学分析
J Cancer. 2024 Oct 21;15(20):6505-6520. doi: 10.7150/jca.101914. eCollection 2024.
10
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.胸膜间皮瘤的免疫治疗:当前和新兴的治疗策略。
Int J Mol Sci. 2024 Oct 9;25(19):10861. doi: 10.3390/ijms251910861.

本文引用的文献

1
Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban.瑞典的职业与间皮瘤:石棉禁令实施27年后男性和女性的最新发病率
Epidemiol Health. 2016 Sep 20;38:e2016039. doi: 10.4178/epih.e2016039. eCollection 2016.
2
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.上皮样分化程度是恶性胸膜间皮瘤生存的一个预测指标。
Ann Thorac Surg. 2017 Mar;103(3):962-966. doi: 10.1016/j.athoracsur.2016.08.063. Epub 2016 Oct 17.
3
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.恶性胸膜间皮瘤生存的决定因素:一项对14228例患者的监测、流行病学及最终结果(SEER)研究
PLoS One. 2015 Dec 14;10(12):e0145039. doi: 10.1371/journal.pone.0145039. eCollection 2015.
4
Changing pattern in malignant mesothelioma survival.恶性间皮瘤生存率的变化模式。
Transl Oncol. 2015 Feb;8(1):35-9. doi: 10.1016/j.tranon.2014.12.002.
5
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.细胞减灭术联合奥沙利铂腹腔热灌注化疗治疗腹膜间皮瘤:初步结果及生存分析
Surg Oncol. 2015 Mar;24(1):41-6. doi: 10.1016/j.suronc.2014.12.002. Epub 2015 Jan 8.
6
United States life tables, 2010.美国生命表,2010年。
Natl Vital Stat Rep. 2014 Nov;63(7):1-63.
7
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.胚系 BAP1 突变的间皮瘤患者的长期生存率提高了 7 倍。
Carcinogenesis. 2015 Jan;36(1):76-81. doi: 10.1093/carcin/bgu227. Epub 2014 Nov 7.
8
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.根治性手术和区域化疗治疗恶性腹膜间皮瘤患者的长期生存相关因素。
Surgery. 2013 Jun;153(6):779-86. doi: 10.1016/j.surg.2013.01.001. Epub 2013 Mar 13.
9
Treatment and survival analyses of malignant mesothelioma in Japan.日本恶性间皮瘤的治疗和生存分析。
Acta Oncol. 2013 May;52(4):803-8. doi: 10.3109/0284186X.2012.709948. Epub 2012 Aug 29.
10
An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.恶性胸膜间皮瘤多模式治疗中辅助化疗的概述。
Cancer Treat Rev. 2013 Feb;39(1):10-7. doi: 10.1016/j.ctrv.2012.03.001. Epub 2012 Mar 27.